<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068938</url>
  </required_header>
  <id_info>
    <org_study_id>X-SCOPE</org_study_id>
    <secondary_id>116MIR08023</secondary_id>
    <secondary_id>428/2008BO1</secondary_id>
    <nct_id>NCT01068938</nct_id>
  </id_info>
  <brief_title>Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter</brief_title>
  <acronym>X-SCOPE</acronym>
  <official_title>Detection of Visual Field Defects and Scotoma Progression in Glaucomatous Optic Neuropathy, Using Short-term Intervals With Automated Scotoma-oriented Perimetry (SCOPE) and the Fast Thresholding Strategy GATE (German Adaptive Threshold Estimation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare three perimetric techniques regarding progression of
      the visual field.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>glaucoma progression</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>open angle glaucoma, glaucoma suspects</arm_group_label>
    <description>risk of progression, Latanoprost monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>three different perimeters: HFA, Octopus, MATRIX</intervention_name>
    <description>visual fields</description>
    <arm_group_label>open angle glaucoma, glaucoma suspects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        University Eye Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  max. ± 8 dpt sph, max. ± 3 dpt cyl

          -  distant visual acuity &gt; 10/20

          -  isocoria, pupil diameter &gt; 3 mm

          -  at least one risk of progression: optic disc (splinter) hemorrhage / cup to disc ratio
             (CDR) &gt; 0.7 / inter-eye asymmetry of CDR &gt;0.2 / notching of the optic disc /retinal
             nerve fibre layer (RNFL) defects / intraocular pressure( IOP) &gt;22 mmHg / central
             corneal thickness &lt; 520 µm / advanced visual field defect stage Aulhorn III / elder
             than 70 years

        Exclusion Criteria:

          -  pregnancy, nursing

          -  diabetic retinopathy

          -  asthma

          -  HIV+ or AIDS

          -  history of epilepsy or significant psychiatric disease

          -  medications known to effect visual field sensitivity

          -  infections (e.g. keratitis, conjunctivitis, uveitis)

          -  severe dry eyes

          -  miotic drug

          -  amblyopia

          -  squint

          -  nystagmus

          -  albinism

          -  any ocular pathology, in either eye, that may interfere with the ability to obtain
             visual fields,disc imaging or accurate IOP readings

          -  keratoconus

          -  intraocular surgery (except for uncomplicated cataract surgery) performed &lt; 3 month
             prior to screening

          -  history or signs of any visual pathway affection other than glaucoma

          -  allergies with regard to topic glaucoma medication

          -  history or presence of macular disease and / or macular edema

          -  ocular trauma

          -  medications known to affect visual field sensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Schiefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Ophthalmology, Institute for Ophthalmic Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Ophthalmology, Institute for Ophthalmic Research</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://iovs.arvojournals.org/article.aspx?articleid=2125766</url>
    <description>Publication</description>
  </link>
  <reference>
    <citation>Schiefer U, Pascual JP, Edmunds B, Feudner E, Hoffmann EM, Johnson CA, Lagrèze WA, Pfeiffer N, Sample PA, Staubach F, Weleber RG, Vonthein R, Krapp E, Paetzold J. Comparison of the new perimetric GATE strategy with conventional full-threshold and SITA standard strategies. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):488-94. doi: 10.1167/iovs.08-2229. Epub 2008 Dec 5.</citation>
    <PMID>19060285</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Ulrich Schiefer</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>visual field</keyword>
  <keyword>perimetry</keyword>
  <keyword>glaucoma progression</keyword>
  <keyword>grid</keyword>
  <keyword>POAG and glaucoma suspects with prostaglandin monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

